Baird lowered the firm’s price target on Humana (HUM) to $297 from $300 and keeps a Neutral rating on the shares as part of an update on the managed care and healthcare facilities group. The firm is increasingly cautious on Medicaid and the healthcare exchange.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana implements measures to expedite approvals
- MA Stars loss for Humana baked into earnings bridge, says Morgan Stanley
- Humana investors assumed low odds of Stars suit success, says Wells Fargo
- Humana loses CMS lawsuit, as expected, says Mizuho
- Humana can refile Stars lawsuit at later date, says Barclays